Live chat software

Technical Analysis Free Video Ebook Sign Up

Premier Trading Videos Sign Up

International Stock Trading Sign Up

SMF Services

Stock Market Video - Stock Trading Video - Trading Videos HGSI

HGSI Human Genome Sciences Earnings, Videos, Technical Analysis, Commentary

Human Genome Sciences HGSI Stock Chart

(HGSI) Human Genome Sciences Trading Videos

Massive Short Squeeze Possible on Human Genome Sciences (HGSI) - 1/25/2012
HGSI Buy Out Rumors Floating Price Action to the Upside - 4/12/2011
Volume Alert Stock Trade HGSI 269,200 Share Big Block Trade - 3/29/2011
Human Genome Sciences HGSI Options Theft on the Opening Bell - 3/10/2011
Bear Raid Derail on HGSI on Benlysta Approval Huge Short Squeeze Expected - 3/9/2011
HGSI Human Genome Sciences Benlysta Approval Impact Personal Level- 3/09/2011
Human Genome Sciences Receives FDA Approval for Benlysta Lupus Drug (VIDEO) - 3/9/2011
Human Genome Sciences Massive Short Interest HGSI Record Put Buying Activity - 3/8/2011
HGSI Bet on Human Genome's Lupus Drug Being Approved Video - 3/7/2011
Option Trading Relatively Heavy Put Activity HGSI $22 & $24 Puts Heaving Buying - 3/7/2011
HGSI Options Trading Video Analysis Heavy Put Buying - 3/7/2011
HGSI Opening Bell Price Action Trading Before Benlysta 3 Days Till FDA - 3/7/2011
HGSI Mid Day Update Huge Volume Blocks 591k 443k GOOG at Highs - 3/3/2011
HGSI Live Coverage of the Citi 2011 Global Health Care Conference - 3/3/2011
HGSI RBC Capital Markets Healthcare Conf Benlysta FDA Date 3/10/2011 - 3/2/2011
Massive Institutional Buying HGSI 500,00 Share Big Block Trades - 3/1/2011
Benlysta & Beyond Human Genome Sciences (HGSI) Exclusive Commentary - 2/27/2011
All Eyes on Human Genome Sciences Benlysta FDA Decision - 2/25/2011
Human Genome HGSI Physcian Q/A on FDA Benlysta Approval Webcast at Leerink Swann - 2/17/2011
Human Genome Sciences, Inc. (NASDAQ: HGSI) 13th Annual BIO CEO and Investor Conference - 2/15/2011
HGSI Big Block Purchase 400,000 on the Closing Bell - 2/10/2011
Human Genome Sciences HGSI Leads Biotech Sector Higher SPA FDA Agreements - 2/10/2011
HGSI Daily Chart Analysis vs Weekly Chart Setup Price Action Above the Market - 1/10/2011

Stock Market Alert HGSI Human Genome Sciences Huge Volume & Price Spike - 1/7/2011

Human Genome Sciences "HGSI" Benlysta Development and Stock Trading Update - 12/15/2010
Human Genome Sciences (HGSI) Technical Analysis History 2011 Biotech Leader Pt 1  - 12/11/2010
Human Genome Sciences (HGSI) Technical Analysis History 2011 Biotech Leader Pt 2  - 12/11/2010
HGSI Human Genome Sciences Record Purchase Volume Purchase $10,000,000 Purchase - 12/08/2010
HGSI Human Genome Sciences Special FDA Dec 9th Approval Date Part 1 - 11/27/2010
HGSI Human Genome Sciences Special FDA Dec 9th Approval Date Part 2 - 11/27/2010
HGSI Glaxo FDA Advisory Committee Recommends Approval of Benlysta  - 11/16/2010
Human Genome Sciences Benlysta Drug Approved by FDA Panel - 11/16/2010
Human Genome Huge Call Volume Alert Huge Buying and Trading Breakout - 11/15/2010
Human Genome Volume Alert Huge Buying Trading Breakout Benlysta FDA Announcement  - 11/15/2010

Human Genome Sciences Trading Video HGSI Sell Order GTC Profit Objective Part 1 - 11/15/2010

Human Genome Sciences Trading Video HGSI Sell Order GTC Profit Objective Part 2 - 11/15/2010

Options Trading Video HGSI Jan 2011 30 Calls 5000 Contracts Purchase - 11/15/2010
Human Genome Sciences Time and Sale Bear Raid FDA Panel - 11/12/2010
Stock Futures Pre Market HGSI Human Genome Sciences Spike $29.50 See Why - 11/12/2010
Biotech Stock Alert: Equity & Options Volume Activity Alert HGSI - 11/12/2010
Arthritis drugs advisory committee fda panel notes - 11/12/2010
Human Genome Sciences Options Volume Alert Massive Call Options Volume Equity Down 10% - 11/12/2010
HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation - 11/12/2010
Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI) - 11/12/2010
Human Genome Sciences Benlysta Drug Approval for Lupus Patients - 11/11/2010
HGSI Huge Stock Trade off the Bottom Opening Bell Wall St - 11/11/2010
HGSI 40 Call Options Trading Video Jan 2011 Call Options - 11/10/2010
HGSI 30 Call Options Trading Video Jan 2011 Call Options -11/10/2010

Human Genome Sciences HGSI Special Biotech Future Video - 11/10/2010

Human Genome Sciences HGSI Big Block Trades Huge Buys Going into the Close - 11/10/2010
What's the next Big Biotech Stock? HGSI "The Next Big Cap BioTech Stock" - 11/10/2010
Human Genome Sciences HGSI Risk Management Trading with Position Management Planning - 11/10/2010
Options Trading Strategy HGSI $10 Put SMF MMT Risk Management Training - 11/4/2010
Options Trading Strategies HGSI $10 Put SMF MMT Risk Management Training - 11/1/2010
Stock Market Trading Trading Profits Entry & Exits Off Bottom HGSI Human Genome Sciences - 10/20/2010
Money Flows into Biotech 397,000 shares on HGSI Stock Rallies Trends Move Higher - 9/30/2010
BIG BLOCK Trade Financial Market Update: Money Flow Biotech Human Genome Sciences "HGSI" - 9/30/2010
Heavy Call Buying Options Trading Activity Stock Alert HGSI $31 Strike Price for October - 9/30/2010
Understanding Stock Market Trading Strategies Bid/Ask Price Manipulation (HGSI) - 9/28/2010
Online Trading Video Pre Market Wall Street Opening Bell Price Action HGSI  - 9/23/2010
Huge Stock Trade! Big Block Stock Purchase on Biotechnology Stock HGSI - 9/23/2010
Closing Bell Stock Market Trading HGSI Double Top Highs Buying Dips - 9/22/2010
HGSI Human Genome Sciences Stock Trading Video Wholesale Entry - 9/22/2010
Stock Market Technical Analysis Human Genome (HGSI) Monthly Chart Bullish Breakout - 9/16/2010
Human Genome HGSI Monthly Chart Bullish Breakout - 9/16/2010
Hot Biotech HGSI Human Genome GlaxoSmithKline (GSK) Announce FDA - 8/19/2010
Biotech Stocks HOT "Biotechnology Sector Upgrade" SMF Special Report BTK.X Index - 8/18/2010
Human Genome HGSI Culminate in the First FDA Approved Drug for Lupus - 8/03/2010
HGSI Human Genome: Expect BLA acceptance near term  - 08/02/2010
Human Genome Takeover Chatter Rumor Round Up Video  - 8/02/2010

Analyst Upgrades & Downgrade History for HGSI

12/10/10 Cowen - Initiated - Underperform

12/7/10 Credit Suisse - Initiated - Outperform

12/6/10 Stifel Nicolaus - Reiterates- Buy

11/17/10 JP Morgan - Reiterates- Overweight

11/17/10 Citigroup - Downgrade - Buy to Hold

11/17/10 Morgan Stanley- Downgrade - Buy to Underperform

9/13/09 Bernstein - Downgrade - Outperform to Market Perform

9/9/10 Stifel Nicolaus - Initiated - Buy

7/22/10 Robert W. Baird - Upgrade - Outperform

6/28/10 JPM Securities - Reiterates- Market Perform

4/1/10 Jesup & Lamont - Initiated - Buy

4/1/10 Collins Stewart - Initiated - Buy

3/12/10 Piper Jaffray - Reiterates - Overweight

1/27/10 RBC Capital Markets - Initiated - Outperform

10/29/10 JP Morgan - Upgrade - Neutral to Outperform

12/21/09 Morgan Stanley - Initiated - Overweight

11/2/09 UBS - Reiterates - Buy

10/29/09 JP Morgan - Upgrade - Neutral to Overweight

10/14/09 Citigroup - Reiterates - Buy

9/14/09 Piper Jaffray- Reiterates - Overweight

9/3/09 UBS - Reiterates - Buy

8/11/09 Leerink Swann - Reiterates - Outperform

8/4/09 ThinkEquity - Upgrade - Accumulate to Buy

7/21/09 ThinkEquity - Upgraded - Source of Funds to Accumulate

7/21/09 Bernstein - Upgrade - Market Perform to Outperform

7/21/09 Citigroup - Upgrade - Hold to Buy

7/20/09 UBS - Upgrade - Neutral to Buy

7/20/09 Lazard Capital Markets - Upgrade - Sell to Hold

7/13/09 UBS - Downgrade - Buy to Neutral

7/12/09 Lazard Capital Markets - Downgrade - Hold to Sell

3/09/09 Piper Jaffray - Downgrade - Buy to Neutral

Full HGSI Upgrade & Downgrade History

Human Genome Sciences Inc.

14200 Shady Grove Road
Rockville, MD 20850-7464
United States
Phone: 301-309-8504
Fax: 301-309-8512
Website: http://www.hgsi.com

DETAILS

Sector:

Healthcare

Industry:Business Services

Full Time Employees: 5,100

BUSINESS SUMMARY

Human Genome Sciences Inc. operates as a biopharmaceutical company in the United States. The companys clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of BENLYSTA for systemic lupus erythematosus; ZALBIN for chronic hepatitis C; and raxibacumab for inhalation anthrax. Its oncology products include Mapatumumab (HGS-ETR1), a Phase II product for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer. In addition, the company focuses on the development of the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences Inc., through a strategic collaboration agreement with GlaxoSmithKline, holds substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease and ischemic stroke; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has an agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of ZALBIN; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Human Genome Sciences Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

Human Genome Sciences Inc EPS History

Earnings Quarter	EPS Est	EPS Actual	% Surprise
September 2010	-.36	-.22	38.9%
June 2010	-.27	-.30	-11.1%
March 2010	-.19	-.26	-36.8%
December 2009	-.10	-.06	40%
Septembere 2009	-.31	-.32	-3.2%